Clinical Trial

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy and safety of targeted CD22/CD19 CAR-T cell immunotherapy for first-line consolidation therapy of high-risk invasive B-cell lymphoma.
Trial Details
NCT Number NCT07094477
Lead Sponsor Daihong Liu
Conditions Lymphoma
Enrollment 50 participants
Start Date 2025-04-01
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-30